Evidence map›Paper›PMID 40552110›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Enhancing 10-HDA production of

Ziting Xu, Chaofan Du, Sheng Gao, Xinrui Yan, Pan Deng, Yuehan Liu, Junqing Wang, Ruiming Wang, Nan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziting XuSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Chaofan DuSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Sheng GaoSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Xinrui YanSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Pan DengSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Yuehan LiuSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Junqing WangSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Ruiming WangSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.
Nan LiSchool of Bioengineering, Qilu University of Technology, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

10-Hydroxy-2-decenoic acid (10-HDA) is a medium-chain α,β-unsaturated carboxylic acid that exists in royal jelly with terminal hydroxylation. It has a broad market value because of its antibacterial, anti-inflammatory, anti-tumor, anti-radiation, and other active functions. The one-step whole-cell catalytic synthesis of 10-HDA by constructing engineered strains has improved the reaction rate to a certain extent compared with the previous two-step method. However, the accumulation of 10-HDA to a certain concentration in engineered

Indexed as

chromosome integrationmedium-chain fatty acidmetabolic engineeringtransporter proteinswhole-cell catalysis

Identifiers

PMID40552110
PMCPMC12183247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.